DexP enhances gluconeogenesis in rabbit kidney due to increased FBPase activity.
In vivo DexP induces the insulin resistance and high plasma cholesterol and TG levels.
Inhibition by DHEA of renal G6Pase might be responsible for its hypoglycemic action.
Testosterone may contribute to the DHEA-induced increase in insulin sensitivity.
Supplementation of DHEA might be beneficial for the therapy of GCs-treated patients.